Trial · NCT05897372
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05897372, Phase 2, Terminated, Iain Bressendorff
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study. Trials, record NCT05897372. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05897372
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
- NCT number
- NCT05897372
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Iain Bressendorff
- Conditions
- Diabetic Kidney Disease
- Interventions
- ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
- First posted
- 2023-06-09
- Last updated
- 2024-09-25
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline | after 9 months of treatment | number of subjects achieving this endpoint |
| Secondary | UACR reduction to less than 70% of baseline | after 9 months of treatment | number of subjects achieving this endpoint |
| Secondary | UACR less than 300 | after 9 months of treatment | number of subjects achieving this endpoint |
| Secondary | difference in UACR | after 9 months of treatment | between-groups difference in UACR |
| Secondary | difference in UACR | after 10 months of treatment (1 month off study drugs) | between-groups difference in UACR |
| Secondary | difference in eGFR | after 9 months of treatment | between-groups difference in eGFR |
| Secondary | difference in eGFR | after 10 months of treatment (1 month off study drugs) | between-groups difference in eGFR |
| Secondary | difference in systolic and diastolic blood pressure | after 9 months of treatment | between-groups difference in blood pressure |
| Secondary | difference in systolic and diastolic blood pressure | after 10 months of treatment (1 month off study drugs) | between-groups difference in blood pressure |
| Secondary | incidence of plasma potassium >5.5 mmol/L | after 9 months of treatment | number of subjects achieving this endpoint |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05897372
GET https://conductscience.org/api/trials/v1/NCT05897372/registered